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Abstract: In the present paper, the antibacterial activity of some 1-benzylbenz-
imidazole derivatives were evaluated against the Gram-negative bacteria Esche-
richia coli. The minimum inhibitory concentration was determined for all the 
compounds. Quantitative structure–activity relationship (QSAR) was employed 
to study the effect of the lipophilicity parameters (log P) on the inhibitory ac-
tivity. Log P values for the target compounds were experimentally determined 
by the “shake-flask” method and calculated by using eight different software 
products. Multiple linear regression was used to correlate the log P values and 
antibacterial activity of the studied benzimidazole derivatives. The results are dis-
cussed based on statistical data. The most acceptable QSAR models for the pre-
diction of the antibacterial activity of the investigated series of benzimidazoles 
were developed. High agreement between the experimental and predicted inhi-
bitory values was obtained. The results of this study indicate that the lipophi-
licity parameter has a significant effect on the antibacterial activity of this class 
of compounds, which simplifies the design of new biologically active molecules. 
Keywords: benzimidazole derivatives; lipophilicity; quantitative structure–acti-
vity relationship; antibacterial; in vitro studies. 
INTRODUCTION 
The benzimidazole nucleus, which is a useful structure for further molecular 
exploration and for the development of new pharmaceutical compounds, has 
been studied intensively. The synthesis of benzimidazoles has received a lot of 
attention owing to the varied biological activity exhibited by a number of these 
compounds.1–7 This class of molecules proved to be very important, as they pos-
sess pharmaceutical properties, including antibacterial, against different strains of 
Gram-positive and Gram-negative bacteria,8–10 antifungal3 and herbicidal11 ac-
tivity. It is also well-known that these molecules are present in a variety of anal-
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gesic,12 anti-oxidant,13,14 anti-allergic15,16 and antitumoral17 agents. Many deri-
vatives of benzimidazole show antiparasitic18 and anthelmintic19 activities. In 
addition, they were confirmed to have moderate in vitro anti-HIV activity.20,21 
The success with these groups of molecules stimulated the search for new 
biologically active derivatives. Understanding the role of chemical structure on 
influencing biological activity is very important.22,23 Progress in the use of quan-
titative structure–activity relationship (QSAR) methods has shown the impor-
tance of the hydrophobic or lipophilic nature of biologically active molecules. 
The lipophilicity modifies the penetration of bioactive molecules through the apolar 
cell membranes. This property is usually characterized by the partition coeffi-
cient (log P), which is essentially determined from distribution studies of the 
compound between an immiscible polar and non-polar solvent pair. This quanti-
tative descriptor of lipophilicity is one of the key determinants of pharmaco-
kinetic properties.24–26 Knowing the exact values for this parameter, it is possible 
to predict the inhibitory activity of the drugs. 
In this context, the aim of the present study was to investigate the activity of 
different substituted benzimidazoles against the Gram-negative bacteria Escheri-
chia coli and to study the quantitative effect of lipophilicity on antibacterial acti-
vity. The objective of this study was to develop a rapid and reliable method for 
predicting the antibacterial activity of this class of molecules, as well as to deter-
mine the best log P values affording the most significant multilinear QSAR mo-
dels, which link the structure of these compounds with their inhibitory activity. 
EXPERIMENTAL 
Modeling of compounds and calculation of lipophilicity parameters 
The investigated compounds (Table I) were synthesized by a procedure described ear-
lier.27 The free on-line JME molecular editor software was used to model these molecules in 
SMILES (simplified molecular input line entry system) format. The SMILES notation created 
by the structure drawing program CambridgeSoft's ChemDrawPro was used as chemical struc-
ture input for all programs, except HyperChem 7.5 (HyperCube Inc., Version 7.5).28 
TABLE I. Structural formula of the compounds 
 
Compound R1 R 2 R 3 R 4 
I-CH3  CH3  H CH3 CH3 
I-Cl Cl  H  CH3 CH3 
I-F F  H  CH3 CH3 
I-OCH3 OCH3 H  CH3 CH3 
II-CH3  CH3 NH2 H  H 
II-Cl Cl  NH2 H  H 
II-F F  NH2 H  H 
II-OCH3  OCH3 NH2 H  H   ANTIBACTERIAL ACTIVITY OF 1-BENZYLBENZIMIDAZOLE DERIVATIVES  969 
TABLE I. Continued 
Compound R1 R 2 R 3 R 4 
III-CH3  CH3 NH2 CH3 CH3 
III-Cl Cl  NH2 CH3 CH3 
III-F F  NH2 CH3 CH3 
III-OCH3  OCH3 NH2 CH3 CH3 
The lipophilicity parameters, based on log P, for all the compounds were experimentally 
determined (the “shake-flask” method) and their values calculated using different theoretical 
procedures from internet data (log PHyper, CSlog P, milog P, ALOGP, IAlogP, CLOGP, log Kow 
and XLOGP) (Table II). 
TABLE II. Lipophilicity descriptors experimentally determined by “shake-flask” method and 
those calculated using different software 
Log P 
Calculated  Cmpd.  Experi-
mental Log PHyper  CSlog P milog P ALOGP IAlogP CLOGP log Kow  XLOGP 
I-CH3  4.85 3.48  4.66 4.32 3.96 4.00 4.80  5.13  4.64 
I-Cl 5.05  3.75  4.46  4.55  4.27 4.27 5.01  5.23  4.83 
I-F 4.50  2.70  3.85  4.03  3.65 3.34 4.44  4.78  3.85 
I-OCH3 4.28  2.31  4.29  3.93  3.55 3.75 4.22  4.67  4.29 
II-CH3  3.60 2.75  3.06 3.32 3.14 2.70 3.56  3.68  3.44 
II-Cl 3.85  2.80  3.48  3.55  3.60  3.06  3.78  3.78  3.62 
II-F 3.25  2.42  2.18  3.03  3.08  3.16  3.21  3.33  3.17 
II-OCH3 3.04  2.03  2.85  2.93  2.83 2.57 2.98  3.21  2.92 
III-CH3  4.55 3.06  4.13 4.12 3.85 3.36 4.51  4.77  4.32 
III-Cl 4.78  3.01 4.41  4.35  4.18  3.65  4.72 4.87 4.50 
III-F 4.20  2.72  3.28  3.84  3.55  2.94  4.16  4.43  4.04 
III-OCH3 3.97  2.34  3.90  3.73  3.46 3.20 3.93  4.31  3.80 
“Shake-flask” method 
Partition coefficients (P) for benzimidazoles between n-octanol and phosphate buffer were 
determined at 25 °C. Before the partitioning of the benzimidazoles, the buffer (0.15 mol L-1, 
pH 7.4) and n-octanol (99 %, Sigma, USA) were saturated with each other. The benzimida-
zoles were dissolved in ethanol (96 %, Zorka, Serbia) at a concentration of 2 mg mL-1 to give 
the stock solutions. Calibration was performed in exactly the same manner as the partitioning, 
except that n-octanol was not used. The amounts of the sample were chosen so that the absor-
bance ( = 252 nm) was between 0.10 and 0.80. The partitioning experiments were performed 
in the systems n-octanol/phosphate buffer 1:20, 1:30, 1:70 and 1:80 (v/v). All the solutions 
were pipetted into glass vials; the n-octanol and stock solution were added with a microliter 
syringe. The phases were shaken together on a mechanical shaker (Viggo, Sweden) for 30 min, 
centrifuged (Rotofix, Switzerland) at 2500 rpm for 20 min to afford complete phase separa-
tion, and the n-octanol phase was removed. The absorbance of the buffer phase was measured 
using a Shimadzu UV/Vis spectrophotometer (Japan) at 252 nm. Log P values were calculated 
using Eq. (1): 
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where P is partition coefficient, y is total mass of benzimidazole derivative (mg), x is the mass 
of benzimidazole derivative in the buffer phase after partitioning (mg), Vbuffer is the volume of 
phosphate buffer (mL) and Vn-octanol is the volume of n-octanol (mL). Each experimental log P 
value is the average of five determinations. 
Calculation methods 
A number of different computer programs for the calculation (prediction) of the lipo-
philicity of chemical compounds, based on their structure, have recently been developed. 
Log PHyper. The computer program HyperChem 7.5 predicts log P values using the atom-ad-
ditive method according to Ghose, Prichett and Crippen.29 The program lists atom contribu-
tions for each atom type and calculates the log P value summing up all the atom contributions. 
CSlog P. This program is based on topological structure descriptors and electropological 
state (E-state) indices.30 
milog P. The milog P 1.2 program calculates log P values as the sum of group contribu-
tions and correction factors.31 
ALOGP. The ALOGPS 2.1 package includes programs to predict lipophilicity and aque-
ous solubility of chemical compounds. The method is based on atom-type E-state indices and 
the associative neural network modeling was developed by Tetko et al.32 This method com-
bines electronic and topological characters to predict lipophilicity of the analyzed molecules. 
IAlogP. This is another calculation program which predicts lipophilicity of chemical 
compounds using neural network algorithms and Molconn-Z indices, including E-state indices 
for atom types.33 
CLOGP. The CLOGP 4.0 program is based on the fragmental method developed by Leo 
and Hansch34 and has become the standard in the field of rational drug design. 
LogKOW. The KoWWin program calculates log P values of organic compounds using the 
atom/fragment contribution (AFC) method developed by Syracuse Research Corporation (SRC).35 
XLOGP. The XLOGP 2.0 is a computer program based on additive atomic contributions 
and calculates log P values according to Wang, Fu and Lai.36,37 
The complete regression analysis, including linear, non-linear and multi-linear regression 
(MLR), were carried out by PASS 2005, GESS 2006, NCSS Statistical Software.38 
Antibacterial investigations 
All the 1-benzylbenzimidazole derivatives were evaluated for their in vitro growth inhi-
bitory activity against Gram-negative bacteria Escherichia coli (АТCC 25922). Antibacterial 
activities of the compounds were tested by the disc-diffusion method under standard condi-
tions using Mueller-Hinton agar medium as described by NCCLS.39 The investigated isolate 
of bacteria was seeded in tubes with nutrient broth (NB). The seeded NB (1 cm
3) was homo-
genized in tubes with 9 cm3 of melted (45 °C) nutrient agar (NA). The homogenous suspen-
sion was poured into Petri dishes. Discs of filter paper (diameter 5 mm) were placed on the 
cool medium. After cooling on the formed solid medium, 210-5 dm3 of the investigated com-
pounds were added by micropipette. After incubation for 24 h at 25–27 °C, the diameters of 
the inhibition (sterile) zone (including disc) were measured (in mm). A diameter of the inhi-
bition zone greater than 8 mm indicates the tested compound was active against the micro-
organism. Every test was performed in triplicate. 
Minimum inhibitory concentration (MIC) was determined by the agar dilution method 
according to guidelines established by the NCCLS standard M7-A5.40 The MIC value of tes-
ted benzimidazoles is defined as the lowest concentration of the compound at which no growth 
of the strain was observed in a period of time and under specified experimental conditions. 
Stock solutions of the compounds were prepared in dimethylformamide (DMF). Further dilu-
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was between 6.25–50 g ml-1. The inoculated plates were then incubated at 35 °C for 16–20 h. 
A control using DMF without any test compound was included. There was no inhibitory ac-
tivity in the wells containing only DMF. The MIC values of the benzimidazoles tested were 
obtained as g ml-1. For further QSAR analyses, the negative logarithms of molar MICs (log 
(1/cMIC)) were used. In order to classify the antibacterial activity comparisons were esta-
blished with antibacterial agents currently employed in therapeutic treatment. The MICs were 
compared with those of ampicillin and gentamicin, which were screened under similar con-
ditions as the tested compounds. 
RESULTS AND DISCUSSION 
The values of antibacterial activity of the benzimidazole derivatives against 
the tested Gram-negative bacteria are summarized in Table III. The screening 
results revealed that the investigated compounds expressed inhibitory activity 
against Escherichia coli. Compounds with a high log 1/cMIC (or low MIC) are the 
best antibacterials. 
TABLE III. Summary of the antibacterial screening 
Compound  MIC / g ml-1 Log  (1/cMIC) 
I-CH3  6.25 4.602 
I-Cl 6.25  4.637 
I-F 6.25  4.609 
I-OCH3 12.5  4.328 
II-CH3  12.5 4.278 
II-Cl 12.5 4.314 
II-F 25.0 3.981 
II-OCH3 50.0  3.704 
III-CH3  6.25 4.627 
III-Cl 6.25 4.659 
III-F 12.5 4.333 
III-OCH3 12.5  4.352 
Ampicillin 12.5  4.446 
Gentamicin  0.780 5.787 
In order to identify the effect of lipophilicity on the inhibitory activity, QSAR 
studies of title compounds were performed. A set of benzimidazoles consisting of 
12 molecules was used for the generation of a multilinear regression model. The 
reference drugs were not included in the generation of the model as they belong 
to a different structural series. An attempt was made to find the structural require-
ment for the inhibition of Gram-negative E. coli using the QSAR Hansch ap-
proach on benzimidazole derivatives. To obtain the quantitative effects of the struc-
tural parameters of benzimidazole derivatives on their antibacterial activity, QSAR 
analysis with nine different partition coefficients (log P) was operated. First, the 
correlation of each one of the log P values with each other was calculated. The 
resulting correlation matrix is represented in Table IV. As is indicated, the calcu-
lated partition coefficients were in good correlation with each other, especially 
milog P, CLOGP, XLOGP and log Kow, as well as the experimentally obtained 
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TABLE IV. Correlation (r) matrix for the lipophilicity descriptors used in this study 
Procedure  “shake-
flask”  Log PHyper CSlog P milog P ALOGP IAlog P CLOGP log Kow XLOGP 
“shake-flask” 1  0.8019 0.9030  0.9971 0.9619 0.8439 0.9998  0.9842 0.9689 
Log PHyper   1  0.6199  0.7800 0.8337  0.7190 0.8052 0.7194  0.7913 
CSlog P    1  0.9176 0.8550  0.7921 0.8997  0.9170  0.8906 
milog P        1  0.9654  0.8434 0.9969  0.9844  0.9928 
ALOGP        1  0.8390 0.9609  0.9092  0.9469 
IAlog  P          1  0.8437  0.8419  0.8513 
CLOGP           1  0.9847  0.9979 
log Kow           1  0.9894 
XLOGP             1  
Usually, lipophilicity parameters are linearly related to pharmacological acti-
vity (MICs), but in the more general case, this relationship is not linear.41,42 
Therefore, a complete regression analysis was made including linear, quadratic 
and cubic relationships. It is apparent from the data presented in Table V that the 
fitting equations improved when resorting to higher order (second or third order) 
polynomials. 
TABLE V. Correlation coefficients (r) calculated for the relationship between log 1/cMIC and 
different log P values 
Procedure Log  (1/cMIC) = alog P + b  Log (1/cMIC) = alog P2 +
+ blog P + c 
Log (1/cMIC) = alogP3 + 
+ blog P2 + clog P + d 
“shake-flask” 0.9384  0.9626  0.9664 
Log PHyper 0.7628  0.8450  0.8490 
CSlog P  0.8206 0.8211  0.8478 
milog P  0.9282  0.9500  0.9549 
ALOGP 0.9077  0.9486  0.9493 
IAlog P  0.7032  0.7646  0.7757 
CLOGP 0.9389  0.9640  0.9672 
log Kow  0.9053 0.9246  0.9443 
XLOGP  0.8706 0.9226  0.9359 
Data from Table V indicates that only two of the aforementioned log P va-
lues are highly correlated with the measured activity. However, the introduction 
of a second parameter improved the statistical indices of the QSAR models but 
the best QSAR models were obtained with three variables with second order poly-
nomials. The resulting models are as follows: 
Log (1/cMIC) = 0.140CLOGP2 + 0.103log Kow2 – 0.491XLOGP2 – 
 –  0.302Clog P – 1.191log Kow + 3.756XLOGP – 0.632  (2) 
  n = 12; r = 0.9855; s = 0.0744; F = 28   
 Log  (1/cMIC) = 0.939milog P2 – 0.881CLOGP2 + 0.136XLOGP2 – 
  – 7.366milog P + 8.136CLOGP – 1.437XLOGP + 3.851  (3) 
 n  = 12; r = 0.9845; s = 0.0782; F = 24.818 
 Log  (1/cMIC) = 0.762ALOGP2 + 0.736log Kow – 1.453XLOGP2 –   ANTIBACTERIAL ACTIVITY OF 1-BENZYLBENZIMIDAZOLE DERIVATIVES  973 
  – 5.246ALOGP – 6.145 log Kow + 11.544XLOGP + 3.277  (4) 
 n  = 12; r = 0.9843; s = 0.0775; F=25.326    
The statistical quality of the resulting models, as depicted in Eqs. (2)–(4), is 
given by the correlation coefficient, r, the standard error of estimation, s, and the pro-
bability factor related to the F-ratio, F. It is noteworthy that all these equations 
were derived using the entire data set of compounds (n = 12) and no outliers were 
identified. The F-values obtained in Eqs. (2)–(4) are statistically significant at the 
99 % level, since all the calculated F values are higher than the tabulated values. 
To estimate the quality with regards to predictive ability of this model, the 
cross-validation statistical technique was applied. This is the most common vali-
dation technique, where a number of modified data sets are created by deleting, 
in each case, one or smaller group of objects from the data in such a way that 
each object is taken away once and only once. For each reduced data set, the mo-
del is calculated, and responses for the deleted objects are predicted from the mo-
del. The simplest and most general cross-validation procedure is the leave-one-
out technique (LOO technique). The estimation of the models quality was based 
on cross-validated parameters viz., the predicted residual sum of squares, PRESS, 
the total sum of squares deviation, SSY, the uncertainty of prediction, SPRESS, the 
cross-validated correlation coefficient,  2
CV r , and the adjusted correlation coef-
ficient,  2
adj r  (Table VI). 
TABLE VI. Cross-validation parameters 
Equation  PRESS SSY  PRESS/SSY SPRESS 
2
CV r  
2
adj r  
(2)  0.1633 0.9417 0.1734 0.1166 0.8266 0.9366 
(3)  0.2114 0.9417 0.2245 0.1327 0.7755 0.9285 
(4)  0.2037 0.9417 0.2163 0.1303 0.7837 0.9299 
PRESS is an important cross-validation parameter as it is a good approxima-
tion of the real predictive error of the models. Its value being less than the SSY 
indicates whether a model predicts better than chance and whether it can be con-
sidered statistically significant. Thus, in view of this, all the three proposed mo-
dels are statistically significant. Furthermore, to be a reasonable QSAR model, 
the PRESS/SSY ratio should be less than 0.40. The data presented in Table VI in-
dicate that this ratio is < 0.23 for all the developed models. From the PRESS and 
SSY, the  2
CV r  and SPRESS statistics can be easily calculated: 
  SSY PRESS r / 1 2
CV    (5) 
 
n
PRESS
SPRESS   (6) 
The high  2
CV r  values observed for all the proposed QSAR models are indi-
cative of their reliability in the prediction of inhibitory activity. However, the 
only way to estimate the true predictive power of a model is to test its ability to 
predict accurately the biological activities of compounds. In order to verify the 
predictive power of the developed models, the predicted log (1/cMIC) values of the 974 PODUNAVAC-KUZMANOVIĆ, CVETKOVIĆ and BARNA 
investigated benzimidazoles were calculated using Eqs. (2)–(4) and compared with 
the experimental values. Based on the magnitude of the residue, there is a close 
agreement between the observed and calculated inhibitory activities (Table VII). 
Furthermore, plots of the linear regression predicted log 1/cMIC values against the 
observed log (1/cMIC) values also favor the models expressed by Eqs. (2)–(4) (Fig. 1). 
TABLE VII. Predicted log (1/cMIC) values of the benzimidazoles tested against E. coli 
Predicting equations and residues 
Compound 
Eq. (2)  Residue Eq.  (3)  Residue Eq.  (4)  Residue 
I-CH3  4.595 0.007 4.590 0.012 4.573 0.029 
I-Cl  4.637 0.000 4.638  –0.001  4.628 0.009 
I-F  4.625 –0.016 4.618 –0.009 4.616 –0.007 
I-OCH3  4.343 –0.015 4.389 –0.061 4.388 –0.060 
II-CH3  4.185 0.093 4.212 0.066 4.285  –0.007 
II-Cl  4.334  –0.020  4.284 0.030 4.300 0.014 
II-F  3.986 –0.005 4.004 –0.023 4.017 –0.036 
II-OCH3  3.727 –0.023 3.717 –0.013 3.709 –0.005 
III-CH3  4.573 0.054 4.648  –0.021  4.557 0.070 
III-Cl  4.657 0.002 4.651 0.008 4.712  –0.053 
III-F  4.435  –0.102  4.327 0.006 4.336  –0.003 
III-OCH3  4.342 0.010 4.342 0.010 4.347 0.005 
 
   
 
Fig. 1. Plots of the predicted versus the 
experimentally observed inhibitory acti-
vity of theinvestigated 1-benzylbenz-
imidazoles against E. coli.   ANTIBACTERIAL ACTIVITY OF 1-BENZYLBENZIMIDAZOLE DERIVATIVES  975 
In order to investigate the existence of a systemic error in the development 
of the QSAR models, the residuals of the predicted log (1/cMIC) values were plot-
ted against the observed log (1/cMIC) values (Fig. 2). The propagation of the re-
siduals on both sides of zero indicates that no systemic error exists in the deve-
lopment of regression models, as suggested by Jalali-Heravi and Kyani.43 
   
 
Fig. 2. Plots of the residual values against the 
experimentally observed log (1/cMIC) values. 
From the three above presented models, it can be concluded that a strong in-
fluence of the partition coefficient, log P, is important for antibacterial activity 
and this parameter is usually related to the pharmacological activity.41,44 This 
evidence was clearly described in the lipid theory advanced by Meyer and Over-
ton. According to this theory, log P is a measure of hydrophobicity, which is im-
portant not only for the penetration and distribution of a drug, but also for the in-
teraction of the drug with receptors. Therefore, it can be suggested that lipophilic 
properties should be checked in the design of potent antibacterial agents as they 
are deciding factors for their activity. 
CONCLUSIONS 
From the results discussed above, it can be concluded that the investigated 
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Gram-negative bacteria Escherichia coli. QSAR analyses were employed to study 
the quantitative effects of the lipophilicity of the benzimidazoles on their antibac-
terial activity. Different lipophilicity parameters were experimentally determined 
by the “shake-flask” method and calculated using eight different software pro-
ducts. A complete regression analysis was performed in which linear, quadratic 
and cubic relationships between the log P values and the antibacterial activity 
(log (1/cMIC)) were employed. The fitting equations improved when higher order 
(second or third order) polynomials were used. Three high quality non-linear struc-
ture–activity models were derived between the log (1/cMIC) and three different 
log P values. The obtained mathematical models were used to predict the inhibit-
tory activity of the investigated benzimidazoles and close agreement between the 
experimental and predicted values was found. The low residual activity and high 
cross-validated r2 values ( 2
CV r ) observed indicate the predictive ability of the de-
veloped QSAR models. It indicates that these models can be successfully applied 
to predict the antibacterial activity of this class of molecules. It can be concluded 
that the partition coefficient, log P, has a strong influence on the antibacterial ac-
tivity and this parameter is usually related to pharmacological activity. 
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ИЗВОД 
УТИЦАЈ ЛИПОФИЛНОСТИ НА АНТИБАКТЕРИЈСКУ АКТИВНОСТ 
НЕКИХ ДЕРИВАТА БЕНЗИМИДАЗОЛА 
С. О. ПОДУНАВАЦ-КУЗМАНОВИЋ1, Д. Д. ЦВЕТКОВИЋ1 и Д. Ј. БАРНА2 
1Tehnolo{ki fakultet, Bulevar Cara Lazara 1, 21000 Novi Sad i 
2Institut za javno zdravqe, Zmaj Jovina 30, 24000 Subotica 
У овом раду испитана је антибактеријска активност неких деривата 1-бензилбензимида-
зола на грам-негативну бактерију Еscherichia coli. Испитивани бензимидазоли in vitro пока-
зују антибактеријску активност и за сва једињења је одређена минимална инхибиторна кон-
центрација. Применом QSАR (quantitative structure–activity relationship) анализе испитане су 
зависности између инхибиторне активности и параметара липофилности, log P. За испити-
вана једињења, log P вредности су одређене експерименталном “shake-flask” методом и изра-
чунате су помоћу осам различитих рачунарских програма. Методом вишеструке регресије 
испитане су корелације између log P вредности и антибактеријске активности деривата бенз-
имидазола. Резултати су продискутовани на основу статистичких података. Развијени су нај-
прихватљивији математички модели за предвиђање антибактеријске активности у оквиру ис-
питиване серије бензимидазола. Добијено је веома добро слагање између експериментално 
одређених и предвиђених вредности инхибиторних активности. Резултати ових испитивања 
показују да параметар липофилности има значајан утицај на антибактеријску активност ис-
питиване класе једињења, што олакшава дизајнирање нових биолошки активних молекула. 
(Примљено 27. фебруара, ревидирано 13. маја 2008)   ANTIBACTERIAL ACTIVITY OF 1-BENZYLBENZIMIDAZOLE DERIVATIVES  977 
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